← Leaderboards
Philip J Goulder
Massachusetts General Hospital
$10,345,162
Attributed
$10,345,162
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $630.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,345,162 · 3
By mechanism
R01$8,213,755 · 2
U01$2,131,407 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Galit Alter$32,273,423
- Gerald P Linette$7,308,810
- Marcus Altfeld$19,256,149
- Todd M Allen$28,600,717
- Smita Kulkarni$3,765,985
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsImmuneSouth AfricaResponseCohortAffectVaccinesViralT-LymphocyteVirusCellsInfectionMothersDesignFundingViremiaInvestigationInsightFutureAgedCohort StudiesGrantBaseEpidemic
Grant awards (25)
Impact of immune sex differences in the first 1000 days of life and in childhood and adolescence$523,560
U01 · FY2025 · AI · contact PI
Impact of immune sex differences in the first 1000 days of life and in childhood and adolescence$527,932
U01 · FY2024 · AI · contact PI
Impact of immune sex differences in the first 1000 days of life and in childhood and adolescence$534,090
U01 · FY2023 · AI · contact PI
Impact of immune sex differences in the first 1000 days of life and in childhood and adolescence$545,825
U01 · FY2022 · AI · contact PI
Maximising Cure Potential in Paediatric HIV Infection$215,997
R01 · FY2021 · AI · contact PI
Maximising Cure Potential in Paediatric HIV Infection$295,247
R01 · FY2020 · AI · contact PI
Maximising Cure Potential in Paediatric HIV Infection$296,268
R01 · FY2019 · AI · contact PI
Maximising Cure Potential in Paediatric HIV Infection$296,268
R01 · FY2018 · AI · contact PI
Maximising Cure Potential in Paediatric HIV Infection$296,268
R01 · FY2017 · AI · contact PI
Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan Afri$630,251
R01 · FY2014 · AI · contact PI
Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan Afri$440,155
R01 · FY2013 · AI · contact PI
Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan Afri$470,261
R01 · FY2012 · AI · contact PI
Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan Afri$473,067
R01 · FY2011 · AI · contact PI
HLA-associated control-lack of control in HIV infection$238,659
R01 · FY2010 · AI · contact PI
HLA-associated control-lack of control in HIV infection$422,528
R01 · FY2009 · AI · contact PI
HLA-associated control-lack of control in HIV infection$228,748
R01 · FY2008 · AI · contact PI
HLA-associated control-lack of control in HIV infection$218,816
R01 · FY2008 · AI · contact PI
HLA-associated control-lack of control in HIV infection$502,735
R01 · FY2007 · AI · contact PI
HLA-associated control-lack of control in HIV infection$502,669
R01 · FY2006 · AI · contact PI
HLA-associated control-lack of control in HIV infection$504,948
R01 · FY2005 · AI
CTL-MEDIATED CONTROL--PEDIATRIC/ADULT C-CLADE INFECTION$441,304
R01 · FY2004 · AI
CTL-MEDIATED CONTROL--PEDIATRIC/ADULT C-CLADE INFECTION$428,974
R01 · FY2003 · AI
CTL-MEDIATED CONTROL--PEDIATRIC/ADULT C-CLADE INFECTION$417,006
R01 · FY2002 · AI
CTL-MEDIATED CONTROL--PEDIATRIC/ADULT C-CLADE INFECTION$571,328
R01 · FY2001 · AI
CTL-MEDIATED CONTROL--PEDIATRIC/ADULT C-CLADE INFECTION$322,258
R01 · FY2000 · AI